Seven Arts Entertainment Inc (SAPX): He has been dead on. Good luck

Play Episode

25min

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Proactive - Interviews for investors

Astral Resoures’ pre-feasibility study on track for June

Astral Resources NL (ASX:AAR) managing director Marc Ducler talked with Proactive about the latest gold recovery results from the Mandilla Gold Project in Western Australia. He shared insights into recent metallurgical test work at the Theia prospect, where 87% gravity recovery and 98% overall recovery were achieved within 24 hours. Ducler highlighted that these strong results support the upcoming mineral resource estimate and pre-feasibility study. The company is optimising the resource estimate using a A$3,500 gold price and current mining and processing cost assumptions. The updated resource model is expected within two weeks, with the pre-feasibility study targeted for release in the June quarter. Ducler also provided an update on Astral’s takeover of Maximus Resources, which has reached a 72% acceptance level. The acquisition adds 330,000oz to Astral’s resource base and provides future infrastructure opportunities. Additionally, the company has active drilling programs, including diamond drilling at Camp Man, an air core program at Feysville, and a 46-hole RC drilling campaign set to begin shortly. For more insights from Astral Resources, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future updates.

Proactive - Interviews for investors

Nextech3D.ai partners with CSM.ai to revolutionize scalable 3D model creation

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce a strategic partnership with CSM.ai, a leading team of AI researchers, product innovators, and digital artists. This collaboration aims to advance the creation of high-quality, cost-efficient 3D models at scale, providing businesses with next-generation product visualization technology. Nextech3D.ai and CSM.ai began working together in early 2025, successfully delivering hundreds of 3D models to customers with faster turnaround times and reduced costs. The partnership enhances Nextech3D.ai’s automated 3D modeling pipeline while leveraging CSM.ai’s deep AI expertise. At the same time, CSM.ai benefits from Nextech3D.ai’s extensive experience in 3D e-commerce applications. By combining resources, the companies aim to further scale production, drive down costs, and unlock new opportunities in the evolving 3D visualization industry, delivering substantial value to businesses and consumers alike. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Followers	80
Posts	27037
Boards Moderated	3
Alias Born	10/11/2011

Volume:	1,115,000
Day Range:	0.0005 - 0.0006
Bid:	0.0005
Ask:	0.0006
Last Trade Time:	3:55:24 PM EDT
Total Trades:	7

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SAPX Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free